Every controlled substance prescription must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice, the standard set out at 21 CFR 1306.04(a). When the Drug Enforcement Administration investigates a prescriber, the chart carries the case, not what the physician recalls about a patient, but what the record shows on the date the prescription was issued. In July 2025, DEA revoked a Florida physician's registration after finding that his files contained no physical examinations, no documented physician-patient relationship, and no basis for 18 controlled substance prescriptions, a decision that shows what the agency reads a chart for first.
The Legitimate Medical Purpose Standard
21 CFR 1306.04(a) provides that a prescription for a controlled substance is effective only if issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice. The regulation places the responsibility for proper prescribing on the prescriber and a separate corresponding responsibility on the pharmacist who fills the prescription; Health Law Alliance covers the pharmacist's side of that duty separately. A valid license and a completed office visit do not satisfy the prescriber's side on their own. In an administrative proceeding, DEA asks whether the specific prescription can be tied to a documented evaluation, a diagnosis, and a treatment rationale recorded at or near the time it was issued.
What DEA Reads the Chart For
DEA's public interest determination weighs a registrant's compliance with applicable state, federal, or local laws relating to controlled substances under 21 U.S.C. Section 823(g)(1), so state prescribing law usually supplies the checklist DEA reads a chart against. In the Florida case, the agency pointed to state rules requiring a complete medical history and physical examination, a written treatment plan with goals and objectives, a documented discussion of risks and benefits, and monitoring for aberrant drug-related behavior at regular-interval visits, with records detailed enough to demonstrate why the course of treatment was undertaken. The recordkeeping obligations for a registrant's business records and prescription files are a related but separate requirement, covered in DEA Recordkeeping: The Audit-Ready Controlled Substance File; this article addresses the clinical record a chart must show, not the registration paperwork.
Recurring Documentation Gaps
The gap DEA found in the Florida matter was total: no exam and no documented relationship for any of the 18 prescriptions. The same standard applies to closer questions: a dose increase, a quantity larger than the patient's history would suggest, or a refill issued before the prior fill's days'-supply would have run out. A chart that never explains why is read the same way as a chart that was never created, the prescription is unsupported. Early refills draw attention quickly because pharmacy claims data and prescription drug monitoring program entries surface the pattern automatically, often before an investigator ever asks for the file.
Correcting the Record Without Altering Closed Entries
A documentation gap discovered internally is not fixed by rewriting the original note. Any entry added after the date of service belongs in a dated, signed addendum that identifies itself as a later entry, never inserted into or backdated onto the original record. DEA and state licensing boards treat an altered entry as evidence of concealment, a materially worse position than an incomplete one. Going forward, the fix is prospective: a documented evaluation, a stated treatment rationale, and a monitoring note at each interval, entered contemporaneously rather than reconstructed later.
A chart that cannot show why a quantity or an early refill was medically necessary fails the legitimate medical purpose standard the same way a chart with no examination at all does.
Why Early Legal Counsel Is Critical
It is critical that prescribers promptly retain experienced healthcare defense counsel upon receiving a DEA subpoena, a records request, or notice that a registration action may follow. Early legal intervention can protect the prescriber's rights, guide how documentation gaps are addressed without altering closed entries, avoid inadvertent admissions during an interview or records production, and allow counsel to communicate with the Diversion Control Division on the prescriber's behalf. Delaying representation narrows the options once DEA issues a DEA order to show cause, the formal notice proposing to revoke or deny a registration, or escalates to an immediate suspension order where the agency finds an imminent danger to public health or safety; the response process is covered separately in Responding to a DEA Order to Show Cause.
How Health Law Alliance Can Help
Health Law Alliance has handled 5,000+ matters across healthcare regulatory and audit defense over 25+ years, including DEA registration actions built on chart documentation. If a diversion investigator has requested records, issued a subpoena, or proposed a registration action tied to your prescribing pattern, contact Health Law Alliance's DEA defense attorneys for a free, confidential consultation before you respond.
